American, British, and Irish researchers published the results of data analysis obtained during the third phase of clinical trials for the drug dupilumab. The study concerned children suffering from severe atopic dermatitis.
According to the presented data, taking this active medication led to the children growing significantly more than expected. Furthermore, this group of patients showed an increased level of bone mineralization biomarker.
The full report on these trials was published in the scientific journal Journal of the American Academy of Dermatology.